Journal profile · Biology
Folia Biologica
ISSN 0015-5500 · eISSN 2533-7602 · Charles University · CZECH REPUBLIC · Bimonthly · Founded 1955
Folia Biologica: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.8; fully open access; review about 3 months (community reports); community-reported acceptance: easy; 26 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Folia Biologica is published by Charles University and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Immunotherapy and Immune Responses, MicroRNA in disease regulation and RNA modifications and cancer, together about 19.6% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Journal of Cellular and Molecular Biology publishes articles describing original research aimed at the elucidation of a wide range of questions of biology and medicine at the cellular and molecular levels. Studies on all organisms as well as on human cells and tissues are welcome.
Source: LetPub
Research area (LetPub): Biology
Main research topics OpenAlex counts of recent articles; shares are approximate
- Immunotherapy and Immune ResponsesImmunology and Microbiology8.6%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology5.8%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology5.2%
- Virus-based gene therapy researchBiochemistry, Genetics and Molecular Biology5%
- Monoclonal and Polyclonal Antibodies ResearchMedicine4.4%
- Immune Cell Function and InteractionImmunology and Microbiology4.4%
- Glycosylation and Glycoproteins ResearchBiochemistry, Genetics and Molecular Biology4.2%
- RNA Interference and Gene DeliveryBiochemistry, Genetics and Molecular Biology4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Biology | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Biology | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Biology | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.8LetPub ·
- CiteScore 2026-06
- 2.1LetPub ·
- SJR 2026-06
- 0.48LetPub ·
- SNIP 2026-06
- 0.49LetPub ·
- h-index
- 29LetPub ·
- h-index
- 38OpenAlex ·
- i10-index
- 292OpenAlex ·
- 2-year mean citedness
- 1.29OpenAlex ·
- Self-citation rate
- 11.1%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 25LetPub ·
Articles by year OpenAlex count · 861 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 20 | 20 | 4 |
| 2025 | 26 | 26 | 19 |
| 2024 | 23 | 23 | 66 |
| 2023 | 25 | 25 | 86 |
| 2022 | 22 | 22 | 110 |
| 2021 | 26 | 26 | 109 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- about 3 monthsLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessLetPub
Every article is open access; authors usually pay an article processing charge (APC).
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Charles University
- Country or region
- CZECH REPUBLIC
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1955
- ISSN
- 0015-5500
- Electronic ISSN
- 2533-7602
- Official links
- Journal homepage ↗LetPub
FAQ
Frequently asked questions about Folia Biologica
What CAS zone is Folia Biologica in?
In the 2025 upgraded edition of the CAS Journal Ranking, Folia Biologica is in Zone 4 of Medicine, and in Zone 4 of the minor category Biology / Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Folia Biologica?
The latest impact factor listed by LetPub is 1.8; CiteScore 2.1, h-index 38.
How long does peer review take at Folia Biologica?
Authors report an average review time of about 3 months; the community-reported acceptance is “Easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Folia Biologica?
According to LetPub and DOAJ records, Folia Biologica is indexed in SCIE and Scopus.
Is Folia Biologica open access, and what is the APC?
Folia Biologica is a fully open-access journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .